Scientific instruments maker Bruker has agreed to buy PhenomeX for about $108 million, marking its entry into the market for functional single-cell biology research systems. PhenomeX supplies an analysis platform that enables researchers to characterize tens of thousands…

  Revolution Medicines, Inc.  a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. today announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more than $1…